Description
Effective testosterone suppression


Effective testosterone suppression
ELIGARD’s innovative in-situ polymeric gel extended delivery system provides controlled drug release enabling consistent suppression of testicular testosterone synthesis throughout the dosing period. [1]
Learn more about ELIGARD’s Clinical Data here.
Clinical DataFlexible dosing


Flexible dosing
ELIGARD offers four (4) dosing options to meet different patient needs. [2]
Learn more about ELIGARD’s Dosage Options here.
Dosage OptionsEnhanced patient experience
Enhanced patient experience
ELIGARD’s subcutaneous injection allows for numerous injection sites contributing to the patient’s comfort level. [3]
Benefits of subcutaneous (SC) injection include:
For patients…
- Is safe for people taking anticoagulants
- Provides a wide range of injection site options
Avoids muscle soreness - Is suitable for patients with little muscle mass
- Has a low risk of bone or nerve damage
For health care professionals…
- Allows for flexibility in site of care — can be administered in semi-private settings (e.g., infusion center)
- Is easy to administer to patients in wheelchairs
- Is safe for patients who are on anticoagulants
- Is suitable for patients with little muscle mass
- Has a lower risk of bone or nerve damage
Chemical makeup


Leuprolide acetate has been used to treat patients with advanced prostate cancer for over 30 years. Leuprolide acetate is a synthetic nonapeptide analog of naturally occurring gonadotropin releasing hormone (GnRH).
When given continuously, it:
- inhibits pituitary gonadotropin secretion
- suppresses testicular and ovarian steroidogenesis.
The analog possesses greater potency than the natural hormone.
The chemical name is 5-oxo-L-prolyl-L-histidyl-L-tryptophyl-L-seryl-L-tyrosyl-D-leucyl-L-leucyl-L-arginyl-N-ethyl-L-prolinamide acetate (salt).
USP <800> considerations
USP General Chapter <800> Hazardous Drugs—Handling in Healthcare Settings is only applicable in the context of compounding. ELIGARD is a conventionally manufactured product, and preparation in accordance with the approved labeling for administration to an individual patient is not considered compounding. Therefore, USP <800> does not apply to the mixing and administration of ELIGARD.
FDA approval
ELIGARD is indicated for the palliative treatment of advanced prostate cancer. The one-month, three-month, four-month, and six-month formulations received FDA approval in Jan 2002, July 2002, Feb 2003 and Dec 2004, respectively.
References
- Sartor O. Eur Urol 2006
- ELIGARD® (leuprolide acetate) for injectable suspension 7.5 mg, 22.5 mg, 30 mg, 45 mg prescribing information. Fort Collins, CO: Tolmar Therapeutics, Inc.; 2019.
- Prettyman J. Urologic Nursing 2019